BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24563328)

  • 1. Expression profiling of breast cancer patients treated with tamoxifen: prognostic or predictive significance.
    Tabarestani S; Ghaderian SM; Rezvani H; Mirfakhraie R
    Med Oncol; 2014 Apr; 31(4):896. PubMed ID: 24563328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
    Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
    Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
    Kim C; Tang G; Pogue-Geile KL; Costantino JP; Baehner FL; Baker J; Cronin MT; Watson D; Shak S; Bohn OL; Fumagalli D; Taniyama Y; Lee A; Reilly ML; Vogel VG; McCaskill-Stevens W; Ford LG; Geyer CE; Wickerham DL; Wolmark N; Paik S
    J Clin Oncol; 2011 Nov; 29(31):4160-7. PubMed ID: 21947828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
    Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R
    J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.
    Alkner S; Jensen MB; Rasmussen BB; Bendahl PO; Fernö M; Rydén L; Mouridsen H;
    Breast Cancer Res Treat; 2017 Nov; 166(2):481-490. PubMed ID: 28766132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
    Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
    Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.
    Alkner S; Bendahl PO; Ehinger A; Lövgren K; Rydén L; Fernö M
    PLoS One; 2016; 11(3):e0150977. PubMed ID: 26959415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer.
    Weiner M; Skoog L; Fornander T; Nordenskjöld B; Sgroi DC; Stål O
    Ann Oncol; 2013 Aug; 24(8):1994-9. PubMed ID: 23670096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen.
    Kerr DA; Wittliff JL
    Horm Cancer; 2011 Oct; 2(5):261-71. PubMed ID: 21826535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen.
    Moon YW; Park S; Sohn JH; Kang DR; Koo JS; Park HS; Chung HC; Park BW
    J Cancer Res Clin Oncol; 2011 Jul; 137(7):1123-30. PubMed ID: 21327800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
    Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
    Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 overexpression and activation, and tamoxifen efficacy in receptor-positive early breast cancer.
    Singer CF; Gschwantler-Kaulich D; Fink-Retter A; Pfeiler G; Walter I; Hudelist G; Helmy S; Spiess AC; Lamm W; Kubista E
    J Cancer Res Clin Oncol; 2009 Jun; 135(6):807-13. PubMed ID: 19034514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
    Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
    Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
    Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K
    Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer.
    McGovern SL; Qi Y; Pusztai L; Symmans WF; Buchholz TA
    Breast Cancer Res; 2012 May; 14(3):R72. PubMed ID: 22559056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification.
    Tabarestani S; Ghaderian SM; Rezvani H; Mirfakhraie R; Ebrahimi A; Attarian H; Rafat J; Ghadyani M; Alavi HA; Kamalian N; Rakhsha A; Azargashb E
    Cell Oncol (Dordr); 2014 Apr; 37(2):107-18. PubMed ID: 24573687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.
    Shi L; Dong B; Li Z; Lu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Wang Z; Xie Y
    J Clin Oncol; 2009 Jul; 27(21):3423-9. PubMed ID: 19487384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.
    Parra-Palau JL; Pedersen K; Peg V; Scaltriti M; Angelini PD; Escorihuela M; Mancilla S; Sánchez Pla A; Ramón Y Cajal S; Baselga J; Arribas J
    Cancer Res; 2010 Nov; 70(21):8537-46. PubMed ID: 20978202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene.
    Chang HG; Kim SJ; Chung KW; Noh DY; Kwon Y; Lee ES; Kang HS
    J Mol Med (Berl); 2005 Feb; 83(2):132-9. PubMed ID: 15536519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.